International Clinical Trial: Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age

Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07207408) titled 'Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age' on Oct. 2.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Dynavax Technologies Corporation

Condition: Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis

Intervention: Biological: rF1V-1018 Biological: rF1V-1018 Biological: rF1V-1018 Biological: rF1V-1018 Biological: rF1V-1018

Recruitment Status: Recru...